接受酪氨酸激酶抑制剂治疗的慢性髓性白血病患者治疗失败预测模型
该研究基于1个中心1955例连续慢性期慢性髓性白血病(CML)患者数据开发酪氨酸激酶抑制剂(TKI)治疗失败的临床预测模型,并在76个其他中心3454例患者中外部验证。模型将患者分为低、中、高危三组,各组治疗失败累积发生率差异显著(P < .001),外部验证区分度和校准度良好,预测区分能力优于Sokal评分和EUTOS长期生存评分。
要点
- 模型基于1955例接受初始伊马替尼或二代TKI治疗的慢性期CML患者开发。
- 模型将患者分为低、中、高危三组,治疗失败累积发生率差异显著(P < .001)。
- 外部验证纳入76个中心3454例患者,区分度和校准度良好。
核心结论
- 该模型可帮助医生估计慢性期CML患者初始伊马替尼或二代TKI治疗失败的可能性。
研究设计与样本
- 研究纳入1个中心1955例连续慢性期CML患者(按欧洲白血病网推荐诊断)接受初始伊马替尼或二代TKI治疗,用于开发TKI治疗失败的临床预测模型。
- 模型在76个其他中心3454例患者中进行外部验证。
主要发现
- 模型将患者分为低、中、高危三组,各组治疗失败累积发生率差异显著(P < .001)。
- 外部验证数据集区分度和校准度良好,表现与训练数据集一致。
- 模型预测区分能力优于Sokal评分和欧洲治疗与结局研究长期生存评分,时间依赖的受试者工作特征曲线下面积值更大,重新定义治疗失败风险的能力更好。
临床怎么用
- 原文结论指出该模型可帮助医生估计慢性期CML患者初始伊马替尼或二代TKI治疗失败的可能性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although tyrosine kinase inhibitor (TKI) therapy has markedly improved the survival of people with chronic-phase chronic myeloid leukemia (CML), 20% to 30% of people still experienced therapy failure. Data from 1955 consecutive patients with chronic-phase CML diagnosed by the European LeukemiaNet recommendations from 1 center receiving initial imatinib or a second-generation (2G) TKI therapy were interrogated to develop a clinical prediction model for TKI-therapy failure. This model was subsequently validated in 3454 patients from 76 other centers. Using the predictive clinical covariates associated with TKI-therapy failure, we developed a model that stratified patients into low-, intermediate- and high-risk subgroups with significantly different cumulative incidences of therapy failure (P < .001). There was good discrimination and calibration in the external validation data set, and the performance was consistent with that of the training data set. Our model had the better prediction discrimination than the Sokal and European Treatment and Outcome Study long-term survival scores, with the greater time-dependent area under the receiver-operator characteristic curve values and a better ability to redefine the risk of therapy failure. Our model could help physicians estimate the likelihood of initial imatinib or 2G TKI-therapy failure in people with chronic-phase CML.
引用
- Zhang X, Liu B, Huang J, et al. A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. Blood. 2024. PMID: 39046786. doi:10.1182/blood.2024024761
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。